Drugs / DBI-102
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05511948 | Aug 2022 → Mar 2023 | hyperpigmentation of the skin | DermBiont, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DBI-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05511948 ↗ |
| Route | Topical | “Topical DBI-102 Gel, 0.8% twice daily for 12 weeks for the randomized cohort” NCT05511948 ↗ |